Cipla employee settles case with SEBI, pays Rs 3 lakh

Published On 2019-09-25 03:55 GMT   |   Update On 2019-09-25 03:55 GMT

SEBI, during its preliminary examination, observed that there was a delay on the part of Pathak in making a disclosure to the company under SEBI's PIT (Prohibition of Insider Trading) norms in respect of change in her shareholding in the scrip of Cipla.


New Delhi: Markets regulator Securities and Exchange Board of India (SEBI), has settled a case with an employee of Cipla for alleged delay in making requisite disclosures regarding her shareholding in the company.


The watchdog has settled the matter with Ranjana Pathak, a designated employee of the company, on payment of Rs 3 lakh towards settlement charges, SEBI said in a settlement order.


The regulator, during its preliminary examination, observed that there was a delay on the part of Pathak in making a disclosure to the company under SEBI's PIT (Prohibition of Insider Trading) norms in respect of change in her shareholding in the scrip of Cipla.


Before proceeding further and initiating proceedings, SEBI issued a settlement notice to Pathak in June, intimating thereby that the proceedings may be settled and disposed of upon filing of a settlement application. Following this, Pathak approached SEBI to settle the case.


"The proposed proceedings that could have been initiated for the defaults...are settled qua the applicant (Pathak)," Sebi said.


SEBI would not initiate any enforcement action against the applicant for the defaults.


The regulator noted that it would have the right to take enforcement actions if it finds that any representation made by the applicant is subsequently discovered to be untrue.


Read Also: Cipla arm, Novartis enter agreement for Ultibro Breezhaler to treat COPD

Article Source : PTI

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News